Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

Sondak VK, Sosman JA.

Semin Cancer Biol. 2003 Dec;13(6):409-15. Review.

PMID:
15001159
2.

Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.

Hsueh EC, Morton DL.

Semin Cancer Biol. 2003 Dec;13(6):401-7. Review.

PMID:
15001158
3.
4.

Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE, Hellström I.

Mol Cancer Ther. 2003 Oct;2(10):995-1002.

5.

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ.

Semin Oncol. 2003 Oct;30(5):667-76. Review.

PMID:
14571414
6.

Overview of antibody therapy in B-cell non-Hodgkin's lymphoma.

Wannesson L, Ghielmini M.

Clin Lymphoma. 2003 Aug;4 Suppl 1:S5-12. Review.

PMID:
14556670
7.

Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.

Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, Cova A, Camerini R, Lewis JJ, Srivastava PK, Parmiani G.

J Immunol. 2003 Oct 1;171(7):3467-74.

8.

Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, Mariani L, Camerini T, Marchianò A, Andreola S, Camerini R, Corsi M, Lewis JJ, Srivastava PK, Parmiani G.

Clin Cancer Res. 2003 Aug 15;9(9):3235-45.

9.

Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.

Chapman PB.

Curr Opin Investig Drugs. 2003 Jun;4(6):710-5. Review.

PMID:
12901230
10.

GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines.

Perales MA, Fantuzzi G, Goldberg SM, Turk MJ, Mortazavi F, Busam K, Houghton AN, Dinarello CA, Wolchok JD.

Cytokines Cell Mol Ther. 2002;7(3):125-33.

PMID:
12850812
11.

Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.

Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S, Tanaka R.

Cancer Immunol Immunother. 2003 Oct;52(10):632-7.

PMID:
12827308
12.

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE.

Hum Gene Ther. 2003 May 20;14(8):709-14.

13.

Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.

Disis ML, Shiota FM, McNeel DG, Knutson KL.

Immunobiology. 2003;207(3):179-86.

PMID:
12777059
14.

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kühl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A.

J Immunol. 2003 Jun 1;170(11):5391-7.

16.

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J.

Cancer Res. 2003 May 1;63(9):2127-33.

17.

Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.

Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD.

Clin Cancer Res. 2003 Apr;9(4):1284-90.

18.

The use of dendritic cells in cancer immunotherapy.

Schuler G, Schuler-Thurner B, Steinman RM.

Curr Opin Immunol. 2003 Apr;15(2):138-47. Review.

PMID:
12633662
19.

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS.

Clin Cancer Res. 2003 Mar;9(3):998-1008.

20.

Epidermal growth factor receptor as a therapeutic target in colorectal cancer.

Cohen RB.

Clin Colorectal Cancer. 2003 Feb;2(4):246-51. Review.

PMID:
12620146
Items per page

Supplemental Content

Support Center